There are no 'safe exposure limits' for phototherapy

British Journal of Dermatology

Volumn 163, Issue 1, 2010, Pages 209-210

  Dawe, R S ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

biological therapy; patient safety; photochemotherapy; phototherapy; psoriasis

Indexed keywords

CYCLOSPORIN A;

CANCER RISK; HUMAN; LETTER; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; RADIATION EXPOSURE; RADIATION INJURY; SKIN CANCER; SYSTEMIC THERAPY; ULTRAVIOLET B RADIATION; WHOLE BODY RADIATION;

DOSE-RESPONSE RELATIONSHIP, RADIATION; GREAT BRITAIN; HUMANS; PHOTOTHERAPY; PRACTICE GUIDELINES AS TOPIC; REFERENCE VALUES; RISK FACTORS;

EID: 77953986381     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09746.x     Document Type: Letter

References (5)

1. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 161 : 987 1019.
2. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998 134 : 1582 1585.
3. Hearn RM, Kerr AC, Rahim KF et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008 159 : 931 935.
4. Diffey BL. Factors affecting the choice of a ceiling on the number of exposures with TL01 ultraviolet B phototherapy. Br J Dermatol 2003 149 : 428 430.
5. Ibbotson SH, Bilsland D, Cox NH et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004 151 : 283 297.